Clinical trials: Deglutition Disorder
Gastroesophageal Reflux Disease (GERD)
A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive
The purpose of the study is to evaluate the pharmacokinetics (how the drug is absorbed in the body, how it is distributed within the body and removed from the body over time), pharmacodynamics (how the study medication affects…
- Trial name
- NCT00747526
- Testing
- Rabeprazole sodium 5 mg, Rabeprazole sodium 10 mg
- Where
- 20 sites in United States, Belgium and 3 more
- Volunteers
- 51 people
- Sponsor
- Janssen Research & Development, LLC
GERD
PPI Test in GP Patients
The purpose of this study is to determine the diagnostic value of two week treatment with Nexium as a confirmatory test for patients with suspected reflux disease.
- Trial name
- NCT00318084
- Testing
- Esomeprazole, Ambulatory 24-hour esophageal pH-monitoring
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux
Study on Hydrotalcite for Relief of Acid Symptoms Due to Acid Rebound After Stopping Long-Term PPI Therapy
This observational study aims to explore the effectiveness of hydrotalcite, marketed as Talcid, in alleviating acid-related symptoms that occur due to an acid rebound after discontinuing a non-/no-longer-indicated long-term…
- Trial name
- NCT07291700
- Testing
- Hydrotalcite (Talcid, BAYX002833)
- Where
- 2 sites in Germany
- Volunteers
- 167 people
- Sponsor
- Bayer
Symptomatic Non-erosive Gastroesophageal Reflux Disease
A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks
The main objective is to assess the efficacy of vonoprazan (10 mg as needed) compared to placebo (as needed) in relief of episodic heartburn at 2 hours that is sustained for 24 hours over 12 weeks of treatment in participants…
- Trial name
- NCT07752407
- Testing
- Vonoprazan
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Phathom Pharmaceuticals, Inc.
Ulcerative Colitis, Crohn Disease
Systems Biology of Gastrointestinal and Related Diseases
This is a longitudinal observational study on patients with gastrointestinal and related disease. The study will be conducted for at least 10 years, following each participant over time, as they either go through relapses and…
- Conditions
- Ulcerative Colitis, Crohn Disease, Obesity, Colon Polyp
- Trial name
- NCT05579444
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Viome
Esophageal Motility Disorders
Esophageal Dysmotility and Dilatation After Laparoscopic Gastric Banding
The purpose of this study is to determine whether esophageal dysmotility and dilatation is an important complication in the long term follow-up following laparoscopic gastric banding for morbid obesity.
- Trial name
- NCT01234428
- Testing
- Laparoscopic surgery, gastric banding
- Where
- Switzerland
- Volunteers
- 167 people
- Sponsor
- Spital STS AG
Esophagitis, Gastro Oesophageal Reflux Disease
Clinical Investigation to Assess the Acid Neutralisation Activity of a Calcite Chewing Gum
This investigation is designed to evaluate the acid neutralisation action of a new test product versus unmatched placebo.
- Trial name
- NCT05129670
- Testing
- Calcite chewing gum
- Where
- Ireland
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Reckitt Benckiser Healthcare (UK) Limited
GERD (Gastroesophageal Reflux Disease)
A Study to Evaluate Tegoprazan as a Diagnostic Tool for GERD
The purpose of this study is to evaluate the diagnostic value of tegoprazan for GERD. Patients experiencing typical GERD symptoms, such as heartburn and acid regurgitation, will take either tegoprazan or a placebo once daily for…
- Trial name
- NCT07826455
- Testing
- Tegoprazan 50 mg
- Volunteers
- 100 people
- Sponsor
- HK inno.N Corporation
Erosive Gastroesophageal Reflux Disease, Non-Erosive Reflux Disease
Efficacy of Pantoprazole in Patients Older Than 12 Years With Reflux Associated Sleep Disorders (PULS)
The aim of the study was to evaluate the effect of Pantoprazole 20 mg/40 mg for 14 days on symptoms in patients with NERD (non-erosive reflux disease) or eGERD (erosive gastroesophageal reflux disease) with special focus on the…
- Trial name
- PULS (NCT00562094)
- Testing
- Pantoprazole
- Where
- 1,153 sites in Germany
- Volunteers
- 8,616 people
- Sponsor
- Nycomed
Gastroesophageal Reflux Disease
A Cross-sectional Study on the Prevalence and Extraesophageal Symptoms of Gastroesophageal Reflux Disease(GERD) in Patients With Upper GI Symptoms, Visiting the Outpatient Departments of Peripheral Hospitals in Greece
The present study has been designed to provide current data on GERD prevalence in several regional areas of Greece outside the two major urban centres (Athens and Thessaloniki), to measure the treatment response in GERD patients…
- Trial name
- GERDQ-XS (NCT01215305)
- Where
- 19 sites in Greece
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
A Study of Dexlansoprazole Modified Release (MR) in Gastroesophageal Reflux Disease (GERD) Participants in the Russian Federation
The primary purpose of the study is to evaluate effect of Dexilant treatment among GERD participants in the Russian Federation.
- Trial name
- INTEGRO (NCT04311541)
- Sponsor
- Takeda
Non-erosive Reflux Disease
A Study to Investigate the Pharmacodynamic Effect After Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population
The purpose of this study is to investigate the pharmacodynamic effect of omeprazole n a Japanese non-erosive reflux disease population
- Trial name
- NCT00259051
- Testing
- Omeprazole
- Where
- 13 sites in Japan
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Laryngopharyngeal Reflux, Throat Pain
Anti-reflux Control to Decrease Post Tonsillectomy Pain
The study aims to determine if treating pediatric patients (age 7-17) for four weeks with omeprazole prior to tonsillectomy will decrease post tonsillectomy pain.
- Trial name
- NCT01777854
- Testing
- Omeprazole
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Ascension Health
GERD, Quality of Life
The Effect of Lifestyle-Adjustments Prior to Medical Treatment on the Effect of Medical Treatment in Reflux Patients
The purpose of this study is to determine whether the improvement in the quality of life after an initial treatment with esomeprazole 40mg for reflux disease is the same in patients who have already made lifestyle-adjustments as…
- Trial name
- NCT00524251
- Testing
- esomeprazole
- Where
- 54 sites in Netherlands
- Volunteers
- 990 people
- Sponsor
- AstraZeneca
GERD
Gastroesophageal Reflux Disease (GERD) Segmentation: Document How Swiss General Practitioners (GPs) Allocate Their GERD Patients to the Three GERD Patient Segments
Document how Swiss GPs allocate their GERD patients to the three GERD patient segments (according to King et al.) and how treated GERD patients are affected by their GERD treatment
- Trial name
- NCT00688675
- Where
- Switzerland
- Volunteers
- 2,912 people
- Sponsor
- AstraZeneca
GERD
Sopran - Omeprazole Treatment Versus Surgery
The purpose of this study is to study gastritis, GI symptoms during long term omeprazole treatment
- Trial name
- NCT00256737
- Testing
- Omeprazole
- Where
- 13 sites in Denmark, Finland and 2 more
- Volunteers
- 219 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux
Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms
The study is designed to assess the effect and safety of oral administration of VECAM 40/300 administered at bedtime compared to Esomeprazole 20 mg administered 30-60 minutes before dinner, for control of nighttime and daytime HB…
- Trial name
- NCT01059383
- Testing
- VECAM 40/300, Esomeprazole 20 mg
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- Vecta Ltd.
Gastroesophageal Reflux Disease (GERD)
Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients
The purpose of this study is to estimate the effect of AZD3355 as an add-on treatment to a Proton Pump Inhibitor (PPI) on Gastroesophageal reflux disease (GERD) symptoms in patients with an incomplete response to PPI treatment.
- Trial name
- NCT00394472
- Testing
- AZD3355
- Where
- 38 sites in Australia, Belgium and 6 more
- Volunteers
- 244 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease, Heartburn
Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI
This study is being carried out to see whether AZD3355 is an effective treatment as an add-on to PPI therapy in patients with Gastroesophageal Reflux Disease (GERD) with a partial response to PPI and to compare this with Proton…
- Conditions
- Gastroesophageal Reflux Disease, Heartburn, Regurgitation
- Trial name
- NCT01005251
- Testing
- lesogaberan (AZD3355)
- Where
- United States
- Volunteers
- 661 people
- Sponsor
- AstraZeneca
Swallowing Disorders
NewBreez Safety and Efficacy Evaluation
The objective of this clinical study is to evaluate the safety and efficacy of the NewBreez intra-laryngeal implant in patients with dysfunctional larynx.
- Trial name
- NCT01587664
- Testing
- NewBreez ILP
- Where
- 2 sites in Belgium, France
- Volunteers
- 2 people
- Sponsor
- ProTiP Medical